Assignee
CAFA THERAPEUTICS LTD
IE·2 granted patents·9 pending applications·10 citations·filing 2017–2021
Top patents by PatentIndex Score
11 records- 0192US11111295B2Antibody for anti-claudin 18A2 and use thereofCAFA THERAPEUTICS LTD·Filed 2017·Granted Sep 7, 2021·7 cites·29 claims
- 0285US11198729B2Immunologic effector cell of targeted CLD18A2, and preparation method and use thereofCAFA THERAPEUTICS LTD·Filed 2019·Granted Dec 14, 2021·3 cites·11 claims
- 0367US2022185880A1Antibody for anti-claudin 18a2 and use thereofCAFA THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 0464US2022017625A1Tumor-specific anti-egfr antibody and application thereofCAFA THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 0562US2022016166A1T-cell expressing chimeric receptorCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 0662US2022017926A1Method for gene editing of cell on the basis of crispr/cas systemCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 0751US2022033491A1Combination therapy of cldn18 antibody and chemotherapy drugsCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 0851US2022096544A1Chemokine expressing cell and use thereofCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 0950US2022127570A1Immune effector cell and use thereofCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 1050US2021292427A1Method for treating tumor using immune effector cellCAFA THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 1149US2022127372A1Tcr fusion protein and cell expressing tcr fusion proteinCAFA THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CAFA THERAPEUTICS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →